New combo therapy aims to tame tough esophageal cancer

This study is testing if adding an immunotherapy drug (tislelizumab) to standard chemotherapy helps people with a specific type of esophageal cancer that is at high risk of returning. It involves 80 participants whose cancer did not fully disappear after initial chemo and radiation. The goal is to see if this combination treatment before and after surgery can better control the cancer and help patients live longer, while avoiding extra treatment for those at lower risk.